Mycenax Biotech Balance Sheet Health
Financial Health criteria checks 5/6
Mycenax Biotech has a total shareholder equity of NT$2.4B and total debt of NT$656.3M, which brings its debt-to-equity ratio to 26.8%. Its total assets and total liabilities are NT$3.8B and NT$1.3B respectively.
Key information
26.8%
Debt to equity ratio
NT$656.32m
Debt
| Interest coverage ratio | n/a |
| Cash | NT$667.69m |
| Equity | NT$2.45b |
| Total liabilities | NT$1.32b |
| Total assets | NT$3.77b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 4726's short term assets (NT$1.1B) exceed its short term liabilities (NT$753.4M).
Long Term Liabilities: 4726's short term assets (NT$1.1B) exceed its long term liabilities (NT$569.8M).
Debt to Equity History and Analysis
Debt Level: 4726 has more cash than its total debt.
Reducing Debt: 4726's debt to equity ratio has increased from 0% to 26.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4726 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 4726 is forecast to have sufficient cash runway for 10 months based on free cash flow estimates, but has since raised additional capital.